RE:RE:RE:RE:RE:RE:RE:Support?After approval with 30/13 label I can see a buyout by GPC and that could cost them $3 billion. It's not just a drug with the same potential as Vyvanse ($2.6 billion buyout). KMPH has a pipeline full of potential blockbusters drugs. 2 orphan drugs and one drug that would be a better version of Vyvanse. An Amphetamine prodrug but super long lasting. Just recently in December 2020 they pushed back the maturity of $7 million debt to 2023. Yesterday they published an sec document that shows that they paid back all of the debt and paid a penalty of $385000 for early repayment. To me that is a clear sign that they want to clean the balance sheet and get out of the grip of the lenders. Now they can negotiate totally independent and if the offer is not high enough then they will just stay a public company and GPC has to pay $500 million milestone payments and 20% royalties for every drug. In the end that would be much more expensive than just buying them out for $3 billion.